ClinicalTrials.gg
Not yet recruitingNCT07700407POPCORNUpdated Jul 14, 2026

Preventing Overdose and Promoting Recovery Through Court Navigation

An interventional study of CourtConnect and Information Only in Substance Use Disorder (SUD), sponsored by RTI International. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by RTI International · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This project is a hybrid type I clinical trial to assess the effectiveness and implementation determinants of a peer-led court navigation program for people who use drugs and are passing through county courthouses. Courthouses are a common point of contact for people with behavioral health needs, but outside of specialty court models, they remain underexplored as a setting for connecting people to substance use disorder treatment and related services. This study will test whether court navigation led by peer recovery specialists can increase receipt of substance use disorder treatment and reduce overdose and incarceration. Peer court navigators will meet with participants in courthouse settings, assess their needs, provide information and referrals, and offer follow-up support for up to 3 months. Peer recovery specialists, who have lived experience with substance use recovery, are increasingly being integrated into criminal legal and community-based settings; however, peer-led court navigation remains an innovative and understudied approach.

02

Conditions studied

  • Substance Use Disorder (SUD)

Keywords

  • court navigation
  • peer recovery coach
  • substance use disorder treatment
  • fatal overdose
  • nonfatal overdose
  • incarceration
  • jail booking
  • prison entry
  • criminal legal system
03

In context

Substance-Related Disorders

2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

This study's planned enrollment of 600 is above the median of 108 across 1,840 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

RTI International is the lead sponsor of 84 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Current resident of Indiana
  • Able to complete study procedures in English
  • Meets at least one of the following criteria: used heroin, fentanyl, methamphetamine, or cocaine in the past 12 months; is interested in resources or treatment for a substance use disorder; or experienced an opioid-related overdose in the past 12 months

Exclusion criteria

Exclusion Criteria:

  • Has been sentenced to incarceration in jail or prison for the next 12 months
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Peer court navigation

    CourtConnect is the intervention. It connects individuals in courthouses with peer court navigators who provide information, referrals, and support to address substance use disorder treatment needs and related health and social needs. Navigation begins in the courthouse and continues in the community through follow-up support for up to 3 months.

    Behavioral: CourtConnect

  • Active comparator
    Information only

    Participants assigned to the information-only group receive information about health and social services in the community from a non-peer research assistant. They do not receive peer court navigation or follow-up support from a peer court navigator.

    Other: Information Only

Interventions

  • BehavioralCourtConnect

    CourtConnect connects individuals in courthouses with peer court navigators who provide information, referrals, and support to address substance use disorder treatment needs and related health and social needs. Navigation begins in the courthouse and continues in the community through follow-up support for up to 3 months.

  • OtherInformation Only

    Participants assigned to the information-only group receive information about health and social services in the community from a non-peer research assistant. They do not receive peer court navigation or follow-up support from a peer court navigator.

06

What researchers measure

Primary outcomes

  1. Administratively documented substance use disorder treatment engagement

    This participant-level outcome will indicate whether a participant has any administratively documented substance use disorder treatment engagement within 90 days after baseline. Treatment engagement will be determined from linked state administrative records, including Medicaid claims for substance use disorder treatment services and prescription drug monitoring program records showing dispensed medications used to treat substance use disorder. For participants without administratively documented substance use disorder treatment during the 90 days before baseline, a qualifying post-baseline record will be classified as treatment initiation. For participants with administratively documented substance use disorder treatment during the 90 days before baseline, a qualifying post-baseline record will be classified as continued treatment engagement. The outcome will be reported as the proportion of participants in each study arm with administratively documented treatment engagement.

    Time frame: 90 days after baseline

Secondary outcomes

  1. Number of participants with a fatal or nonfatal overdose

    Fatal and nonfatal overdose will be measured using statewide vital records and emergency medical records from ambulance services and hospital emergency departments. Participants will be classified as having experienced an overdose if records show a fatal overdose or an encounter for a nonfatal overdose during the 12 months after baseline.

    Time frame: 12 months after baseline

  2. Number of participants with a jail booking or prison entry

    Incarceration through jail booking or prison entry will be measured using statewide criminal legal records. Participants will be classified as having experienced incarceration if records show a booking into a jail facility or entry into the state prison system during the 12 months after baseline.

    Time frame: 12 months after baseline

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The investigators will enroll 600 subjects over 24 months with 12 months of follow-up data by linking administrative records (e.g., prescription fills, emergency department/emergency medical services encounters, mortality, arrests/jail bookings) to survey contents that will include demographics, substance use disorder and treatment history, criminal legal system involvement, social constructs (self-efficacy, motivation, stigma), and harmonized measures. The National Institutes of Health requires that the study team release study data. The investigators will preserve and share de-identified survey datasets (with codebooks), and project documentation (protocols, instruments); derived variables from linked administrative data will be shared, while raw state administrative source files obtained under data use agreements will not be shared. The publicly released scientific data will include only fully de-identified data.

Supporting information: Study protocol, Analytic code

Time frame: IPD and additional supporting information will be archived in the National Addiction \& HIV Data Archive Program (NAHDAP), assigned persistent identifiers, and made available as soon as possible and no later than the earlier of the primary publication or the end of the performance period, whichever comes first.

Access criteria: After project completion, only de-identified datasets will be made available as public-use files and deposited in repositories for broader research, teaching, replication. Shared data will be provided in open, non-proprietary formats, along with parallel Stata/R scripts and a README so that no specialized software is required to access or manipulate the data. Publicly shared datasets will receive a DOI to facilitate sharing, citation, and version control. Access will be controlled when there is any non-trivial re-identification risk or when required by data use agreements. In those cases, repositories will gate access under standard data use agreements that prohibit re-identification and onward sharing, require secure storage and destruction at project end, and log requestor credentials and approved uses. Raw state administrative source files received under data use agreements will not be shared; only de-identified, derived variables constructed from those sources will be deposited.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07700407
Lead sponsor
RTI International
Responsible party
Bradley Ray (Principal Investigator, Senior Research Public Health Analyst 1, RTI International) — Principal investigator
First posted
Jul 14, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
May 2030 (estimated)
Last update
Jul 14, 2026

Study contacts

Bradley Ray, PhD
Contact
bradleyray@rti.org
919-324-5492
Cari Megerian, MPH
Contact
cmegerian@rti.org
415-412-0830

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion